Label: NYSTATIN powder

  • NDC Code(s): 69315-306-15, 69315-306-30, 69315-306-60
  • Packager: Leading Pharma, LLC
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated April 23, 2018

If you are a consumer or patient please visit this version.


    Nystatin is a polyene antifungal antibiotic obtained from Streptomyces noursei. The molecular formula for Nystatin is C47H75NO17. The molecular weight of Nystatin is 926.1.
    Structural formula:


    Nystatin topical powder is for dermatologic use.
    Nystatin topical powder contains 100,000 nystatin units per gram dispersed in talc.



    Nystatin is not absorbed from intact skin or mucous membrane.


    Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes.

    Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed.

    Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.


    Nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species.

    Nystatin topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use.


    Nystatin topical powder is contraindicated in patients with a history of hypersensitivity to any of its components.



    Nystatin topical powder should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.

    If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens


    Patients using this medication should receive the following information and instructions:
    1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.
    2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.
    3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly.

    Laboratory Tests

    If there is lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.


    Teratogenic Effects

    Category C

    Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical powder should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

    Nursing Mothers

    It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

    Pediatric Use

    Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See DOSAGE AND ADMINISTRATION).

    Geriatric Use

    Clinical studies with nystatin topical powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.


    The frequency of adverse events reported in patients using nystatin topical powder is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS, General).


    Very moist lesions are best treated with the topical dusting powder.

    Adults and Pediatric Patients (Neonates and Older)

    Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.


    Nystatin topical powder is supplied as 100,000 units nystatin per gram in plastic squeeze bottles:

    15g (NDC 69315-306-15)

    30g (NDC 69315-306-30)

    60g (NDC 69315-306-60)


    Store at 20°C to 25°C (68°F to 77°F)[see USP Controlled Room Temperature]; avoid excessive heat (40°C/104°F).

    Keep tightly closed.

    Manufactured for:

    Leading Pharma LLC, Fairfield, NJ 07004

    Manufactured by:

    Lyne Laboratories, Inc. Brockton, MA 02301




    nystatin powder
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:69315-306
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Inactive Ingredients
    Ingredient NameStrength
    TALC (UNII: 7SEV7J4R1U)  
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:69315-306-1515 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product04/23/2018
    2NDC:69315-306-3030 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product04/23/2018
    3NDC:69315-306-6060 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product04/23/2018
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Labeler - Leading Pharma, LLC (079575060)
    Registrant - Lyne Laboratories, Inc (053510459)
    NameAddressID/FEIBusiness Operations
    Lyne Laboratories, Inc053510459manufacture(69315-306)